Immunity to malaria develops gradually, after several attacks and over many years (12) . It has long been known that malaria induces a detectable humoral response in humans. The successful passive transfer of malarial immunity in human subjects by means of gamma globulin from immune West Africans (3) focused attention on the protective nature of at least some malarial antibodies and implied that humoral mechanisms constituted a significant effector component of human immunoresponsiveness. A major thrust in malaria has thus been to identify these host-protective antibodies and their target antigens.
An unusual feature of almost all malarial antigens studied to date is the extensive array of tandemly repeating amino acid sequences (10) . These repeats are immunodominant in the sense that much of the human antibody response is directed towards them. It has been observed that many nonimmune individuals have very high levels of antibodies to many repetitive antigens, and it has been suggested that this hyperstimulation of irrelevant B cells leads to a less effective immune response against critical protective epitopes; thus, the repeats are acting as a "smokescreen" (1) . In addition to the repetitive epitopes, Plasmodiulm falciparum encodes an enormous number of cross-reactive epitopes, which are also postulated to be responsible for immune evasion (1) . Therefore, it is desirable to identify those epitopes which may be protective but are perhaps obscured by the dominant immune response to the repetitive and the cross-reactive epitopes.
Screening of P. falciparum expression libraries with immune sera from protected individuals has been performed earlier, and a number of antigens have been identified, but indeed, most of these were found to be antigens containing repetitive domains (1, 4, 5, 10) . No comparisons between sera from malaria-susceptible and -immune persons have been made to date. Thus, in an attempt to target antigenic determinants which react exclusively with the immune sera, we performed a differential screening of an expression library of the parasite with sera from healthy, adult residents of malaria-endemic areas who had not shown malarial symptoms for at least the previous 3 years and with sera from malaria patients actively presenting malarial symptoms at the time of serum collection. In this article, we present the results of such a screen, which yielded eight expression clones that react exclusively but extensively with the immune sera.
MATERIALS AND METHODS
Expression library. The Xgtl 1 cDNA expression library was a gift from G. N. Godson, New York University Medical Center. It was constructed from total parasite RNA isolated from the asexual erythrocytic stages of the FCR-3 strain of P. falciparum (18 (Table 2 ). All 10 clones remained nonreactive with these sera after plaque purification. Another 23 serum samples from malarial patients living in the same endemic region as the donors of the immune sera were used for further screening, and 2 of the 10 clones showed positive reactivities with single serum samples ( Table 2) . A representative screening with patient and immune sera is shown in Fig. 1 . In all, 70 patient serum samples were used to test these clones, and eight of the expression clones remained nonreactive to this lot.
To have any significance regarding clinical protection, the epitopes encoded by these clones should be recognized by the bulk of the immune sera. 10 clones reacted with probes made from these genes ( Fig.  2A) . In a control reaction, the same probe was shown to light up 3.5 ng of the S-antigen DNA. Inserts of five of the eight differential cDNA clones were used for cross-hybridization studies with the other clones. No cross-hybridization was obtained when such a study was performed. This showed that at least five of the eight clones coded for unique epitopes. A representative blot, using the insert from Pf 10, is shown in Fig. 2B , where a specific signal is seen only with DNA from phage Pf 10. Fig. 3 and 4) . The A+T contents of Pf 4 and Pf 10 inserts were 71 and 54%, respectively. The sequences were analyzed by the FASTA program of GenBank (13) (Fig. 2C) . The same result was obtained with the inserts of clones 9, 4, and 2 (data not shown), thus confirming that these four clones indeed have a P. falciparum origin. A Southern blot analysis revealed that at least two of the clones, Pf 4 and Pf 3, were not the same genes, as they hybridized to different bands in the genomic blot (8a).
A protein homology search was performed on the predicted amino acid sequences by using the FASTA program with these two sequences and the EMBL data bank (13) . The only significant matches observed for Pf 4 and Pf 10 are shown in Fig. 5 . Pf 4 showed 53.8% identity in a 52-amino-acid overlap, with the 60S ribosomal phosphoprotein P0 of human origin, while Pf 10 showed about 30% identity over a 30-amino-acid overlap with the M2 matrix protein of influenza virus of various origins. Pf 10 also showed a 17% identity in a 126-amino-acid overlap with the major capsid protein of varicella-zoster virus (data not shown).
DISCUSSION
This study describes an attempt to isolate novel, putative protective antigens of P. falciparum. As shown in Table 1 , 47 of 65 expression clones reacted with all sets of serum samples tested. These, therefore, encode epitopes that are possibly the immunodominant and cross-reactive epitopes of P. falciparum (4, 10) . There were eight clones that reacted with certain pools and not with others. These may be antigenically diverse epitopes of P. falciparum, the positive responses indicating common molecular epitopes between the FCR-3 strain and certain Indian strains. However, the differential responses of these eight clones are more likely to be due to the differential immune response of individuals since no definitive correlation was observed for sera obtained from a particular locality. The possibility of antigenic diversity, or a genetically restricted immune response causing the exclusive reaction of the 10 clones with the immune sera collected from Orissa, was eliminated by the use of a set of patient serum samples from the same endemic area, i.e., Orissa ( Table 2) . Two determinants, Pf 5 and Pf 6, were indeed found to react with single serum samples obtained from patients from Orissa. These may be the candidates for antigenically diverse epitopes. However, eight of the expression clones did not react with any of the 70 patient serum samples tested, whereas they were immunopositive with at least 43% of the 92 immune serum samples tested (Table 3) .
Approximately 40 genes coding for various surface antigens of P. falciparum have been cloned and sequenced at least in part. Many of them have been isolated by screening expression libraries with clinical sera or monoclonal antibodies (1, 4, 5, 9, 10). This study shows that the differential serological screen that we employed resulted in the identification of 10 expression clones that were different from nine common antigens of P. falciparum ( Fig. 2A) . Further analysis showed that two of these are indeed novel epitopes, without any repetitive regions ( Fig.  3 and 4) . Pf of the patient serum samples used in our screening were obtained from adults living in an endemic area and may contain antibodies against epitopes that are important for protection. Indeed, serum samples that reacted with Pf5 and Pf6 might belong to this category.
This differential screen was designed to isolate expression clones of P. falciparum against which antibodies were present only in malaria-immune persons, and therefore, they may be putative protective antigens. However, these immune persons have been exposed to repeated attacks of malaria, and thus it was anticipated that along with antibodies relevant for the immune response, there may be antibodies against nonsurface proteins as well. Especially, autoantibodies against protein domains of P. falciparum which are conserved between humans and parasites may be raised in such a set of immune persons. If Pf 4 turns out to be the P. falciparum equivalent for the ribosomal protein P., it would belong to such a class of protein domain. To date, only the amino acid sequence of the human P0 phosphoriboprotein is available (15) , and therefore it is difficult to predict whether this homologous domain is conserved in all organisms. It would, nevertheless, be important to characterize this protein of P. falciparum since ribosomes form a prime target for drugs.
The matrix protein M2 of the influenza virus is a protein that is expressed abundantly on the infected cell surface (11) . M2 is a type III membrane protein with 24 N-terminal residues in the lumen, 54 residues in the cytosol, and a single membranespanning segment (11) . The homology of M2 with Pf 10 starts from the membrane-spanning domain and continues in the cytosolic domain. M2 has recently been shown to be an Pf 4 and the human 60S ribosomal phosphoprotein PO (15 (14) . Further characterizations of Pf 10 will determine whether it plays an equivalent role in P. falciparum.
